About 4 results found for searched term "IV-255" (0.13 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41656 | IV-255 | Epigenetic Reader Domain |
| IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain. | ||
| M11264 | KI-7 | Adenosine Receptor |
| Ki-7 is an A2B adenosine receptor positive allosteric regulator. Ki-7 enhances cAMP accumulation induced by NECA, a non-selective A2B adenosine receptor agonist (EC50=445.8 nM). Ki-7 also enhanced selective A2B adenosine receptor agonist BAY 60-6583 and adenosine-induced cAMP accumulation with EC50 of 2390 nM and 2550 nM, respectively. | ||
| M11473 | BAY 2666605 | Others |
| BAY 2666605 is an oral active PDE3A and PDE3B inhibitor with IC50 of 87 nM and 50 nM, respectively. BAY 2666605 is a pDE3A-SLFN12 compound inducer (WO2019025562A1; Example, 135). | ||
| M20833 | Vodobatinib (K0706) | Src-bcr-Abl |
| SCO-088, SUN K706, SUN-K0706 | ||
| Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
